Regencell Bioscience
31 hedge funds and large institutions have $16.5M invested in Regencell Bioscience in 2026 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 4 closing their positions.
350% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 4
82% more funds holding
Funds holding: 17 → 31 (+14)
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
43% more capital invested
Capital invested by funds: $11.5M → $16.5M (+$4.94M)
0.02% more ownership
Funds ownership: 0.11% → 0.13% (+0.02%)
37% less call options, than puts
Call options by funds: $1.74M | Put options by funds: $2.78M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MG
Marex Group
London,
|
+$894K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$893K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$485K |
| 4 |
State Street
Boston,
Massachusetts
|
+$335K |
| 5 |
Legal & General Group
London,
United Kingdom
|
+$280K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$317K |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$275K |
| 3 |
SFCM
Seven Fleet Capital Management
Mountain View,
California
|
-$92.4K |
| 4 |
Morgan Stanley
New York
|
-$38.1K |
| 5 |
QL
Quarry LP
New York
|
-$9.83K |
RGC Hedge Fund Activity: Q1 2026 in Review
31 of the 8,128 institutional investors tracked by Wall St. Rank reported a position in Regencell Bioscience (RGC) for Q1 2026, worth a combined $16.5M — up 43% from $11.5M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new RGC positions and 4 closed out — a net gain of 14 holders — while 6 added to existing stakes and 4 trimmed.
The largest buyer was Marex Group, opening a new position worth an estimated $894K. The largest seller was XTX Topco, exiting entirely with an estimated $317K sold.
- 31 institutional investors held Regencell Bioscience (RGC) as of Q1 2026, up from 17 in Q4 2025.
- Funds reported $16.5M of Regencell Bioscience stock for Q1 2026, up 43% quarter-over-quarter.
- 18 funds opened new Regencell Bioscience positions in Q1 2026 and 4 closed out, a net change of +14 holders.
- The largest Regencell Bioscience buyer in Q1 2026 was Marex Group, an estimated $894K added.
- The largest Regencell Bioscience seller in Q1 2026 was XTX Topco, an estimated $317K sold.
Based on aggregated 13F filings for Q1 2026.